To explore the benefit of the HER2/HER4 pathway for cardiomyocyte functions, a more selective agonist is desired to circumvent the wider tissue expression of HER3 and avoid the neuregulin-HER3 axis in tumor biology18,19. The gene discussed is ERBB3; the disease is neoplasm.